Economic growth anchored in social justice under all Cong. govts: Bhatti

Economic growth anchored in social justice remains at the core of Congress governments and the work being undertaken in Telangana under Chief Minister A. Revanth Reddy is a reflection of this conviction, Deputy Chief Minister Mallu Bhatti Vikramarka said here on Friday.
Addressing the 6th edition of CSR and Sustainability Conference and Awards for 2024, organised by Assocham Southern Region, the Deputy CM said, 'In Telangana, we are shaping a new development narrative, one that does not separate economics from ethics. We are committed to building a State that is fiscally responsible, socially inclusive and environmentally conscious.'
Look beyond balance sheets
Asserting that true development is one that empowers people to stand on their feet, especially in today's 'world of unprecedented resources and extraordinary inequality,' Mr. Vikramarka urged business leaders to look beyond balance sheets to a future we are shaping together. Let us not act not out of charity but out of shared responsibility… work for transformation and build societies that flourish.'
Telangana is an ideal destination for corporate social responsibility (CSR) initiatives. The State provides a platform not just to fulfill CSR mandates, but to do so with 100% impact and transparency. He called upon companies across India to consider Telangana as a prime hub for their CSR investments.
The State offers an industry-friendly ecosystem where there are no language barriers; law and order is maintained; and offering abundant, affordable skilled human resources, which the government had set out to enhance with initiatives such as the Young India integrated residential schools and the Young India Skills University. Above all, the State has a proactive, friendly government, the Deputy Chief Minister said.
Telangana's competition is not as much with other Indian states as with developed nations. In sectors like healthcare, pharma, IT, and agriculture produce, the State has set an unmatched trajectory, he added.
Real purpose of CSR is not ticking the box but recognising that growth without inclusion is fragile and that profits without purpose are hollow. Sustainability is not only about the environment, it is about human dignity too, he said.
Assocham in a release said that special addresses, and panel discussions on various topics formed part of the conference. Over 20 organisations were presented awards across various categories for their contributions in CSR and sustainability.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Standard

20 minutes ago

• Business Standard

Amit Shah a disgrace to the post once held by Sardar Patel: Jairam Ramesh

Congress General Secretary Jairam Ramesh on Friday launched a direct attack on Union Home Minister Amit Shah, accusing him of failing to "bring the terrorists who carried out the brutal terror attacks in Pahalgam to justice," and restoring peace in Manipur. "Amit Shah is a disgrace to the position once held by the indomitable Sardar," claimed Ramesh. "The Union Home Minister has failed singularly in bringing the terrorists who carried out the brutal terror attacks in Pahalgam to justice. These terrorists had reportedly also been involved in terror attacks at Poonch (Dec 2023) and at Gagangir and Gulmarg (Oct 2024)," his post said. "The Union Home Minister has failed miserably to restore even a semblance of peace and normalcy in Manipur. All that he has accomplished is to provide guaranteed employment to his son. Now the Union Home Minister makes the most ridiculous of statements. Millions of Indians each speak more Indian languages - in addition to English - than him. He is a disgrace to the position once held by the indomitable Sardar," said the post from Ramesh. Ramesh called the visit a "publicity-driven exercise" that fails to address the ground realities of the state. "The advertisement-loving Prime Minister is once again on a tour of matter how many fake announcements the Prime Minister makes, no matter how many ribbons he cuts for free advertising, the truth is that the double engine government in Bihar has completely failed to meet the expectations of the common people," his post read. "In Bihar, oppression against the deprived classes is at its peak, the law and order situation is extremely bad, criminals have become unbridled and the common citizens are helpless. Every day there are reports of murder, robbery and violence against youth do not have any employment in the state and they are forced to migrate from Bihar," he said. "During this visit, the Prime Minister will also express his electoral concern about the pollution of Mother Ganga .But the truth is that in the last 11 years, 'Ganga cleansing' has become just an election slogan, which is suddenly remembered before every election. Not only in Bihar, Mother Ganga has become more polluted than before in the entire country. Most of the schemes launched in the name of Ganga cleanliness campaign have proved to be a black hole of corruption-After the foundation stone laying, inauguration and heavy publicity, neither any work is visible nor any concrete National Green Tribunal (NGT) itself is exposing the terrible condition of Ganga pollution in Patna and Bihar," added Ramesh.

Hindustan Times

21 minutes ago

• Hindustan Times

15% minority housing quota not new, says Karnataka minister

Karnataka Housing and Minority Welfare Minister Zameer Ahmed Khan on Friday defended the state cabinet's decision to increase reservation for minorities in housing schemes from 10 to 15%, saying the move is based on a recommendation made in 2019 and is not a recent or arbitrary decision. Housing and Minority Welfare Minister Zameer Ahmed Khan said the move is based on a recommendation made in 2019 and is not a recent or arbitrary decision (File photo) 'Decision to reserve 15% for minorities in housing schemes is not a decision taken now. The cabinet subcommittee formed in 2019 when HD Kumaraswamy was the chief minister in the coalition government had recommended it,' Khan said, responding to growing criticism from the opposition. He further clarified that the reservation percentage mirrors existing central policy. 'The central government already provides a 15% quota for minorities under housing schemes, as per the Sachar Committee report. There was a demand that the same should be given in the state. Therefore, the central model has been followed,' he said. The state cabinet approved the hike on Thursday, applying it to all housing schemes under the Urban and Rural Development Departments. The announcement sparked a sharp backlash from the Bharatiya Janata Party (BJP), which labelled the decision 'unconstitutional' and accused the ruling Congress of communal appeasement and vote-bank politics. Khan defended the move on humanitarian grounds, pointing to the acute housing shortage faced by many minority families. 'The existing 10% reservation rate has been increased to 15. There are more poor families in the minority community and the number of homeless people has increased. Hence, there was a demand to increase the reservation rate,' he explained. He also cited a 2021 recommendation from the National Commission for Minorities, which had called for the implementation of a 15% reservation in housing schemes. 'Without understanding these factual points, the opposition parties are making unnecessary criticisms, which is not appropriate,' Khan added. Meanwhile, chief minister Siddaramaiah said his government's decision to enhance reservation for minorities under housing schemes in the state from 10 to 15% was in line with the Union government's guidelines. He termed the BJP's criticism of it as 'hypocritical and politically motivated', and asserted that his government rejects the politics of hatred and division being pushed by the opposition party. In a statement, he said this is based on the Prime Minister's 15-Point Programme for the Welfare of Minorities (2019), which clearly directs all Central and State implementing agencies to earmark 15%of physical and financial targets for minorities wherever possible. Reacting to it, senior BJP leader and former chief minister BS Yediyurappa accused the Congress government of creating social divisions. 'This government is unnecessarily creating problems... But there is a limit to everything. So if they want to increase it, they should do it for everyone and all communities. This is not correct; that is why everyone is opposing it,' he said. State BJP president Vijayendra Yediyurappa echoed his father's concerns, taking to social media to term the move a form of religious favouritism. 'Reservation on the basis of religion is unconstitutional! @INCKarnataka in Karnataka has converted welfare into a marketplace for vote-bank politics. First, 4% quota in government contracts. Now, 15 per cent quota in housing schemes. Where does this appeasement end?' he wrote on X. He argued that the decision risks marginalising Scheduled Castes, Scheduled Tribes, and Other Backward Classes by reducing their share of benefits. 'This is a dangerous attempt to institutionalise communal vote-bank politics. It not only robs SCs, STs, and OBCs of their rightful opportunities, but also sends a disturbing message that merit, backwardness, and constitutional principles are secondary to religious appeasement,' Vijayendra posted. With PTI inputs

Mint

29 minutes ago

• Mint

Four Indian pharma stocks that may be hit by US pharma tariff threat

Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from